Intellectual Property and Regenerative Medicine: What Does ‘Freedom to Operate’ Really Mean?

October 29, 2008
Biomaterials Science and Regenerative Medicine: Accelerating the Bench-to-Bedside Trajectory for Regenerative Therapeutics
Hyatt RegencyNew Brunswick, New Jersey

Peter J. Butch III, a partner with Fox Rothschild LLP, spoke at the 9th New Jersey Symposium on “Biomaterials Science and Regenerative Medicine: Accelerating the Bench-to-Bedside Trajectory for Regenerative Therapeutics.” The symposium was held at the Hyatt Regency in New Brunswick, New Jersey, on October 29-31, 2008.

Butch was a panelist on a session held Friday morning, October 31, entitled “Barriers to Adoption and Development of New Therapies,” to which he contributed “Intellectual Property and Regenerative Medicine: What Does ‘Freedom to Operate’ Really Mean?” Additional topics at the session included “Training for New Procedures and Products,” “Developing Technologies for Military Applications” and “Tailoring New Technologies for Changing Environments.”

As a member of Fox Rothschild’s Intellectual Property Practice, Butch focuses his practice in all fields of intellectual property law, with particular emphasis in procuring domestic and international patents on developments involving complex organic and inorganic chemistry, including pharmaceutical, biotechnology and bioinformatics developments. He also has experience in preparing infringement and validity opinions, and negotiating and drafting license agreements. He has prepared and prosecuted domestic and international patent applications for over 20 years for Professor Joachim Kohn on behalf of Rutgers University.

Before entering the law field, Butch received a B.S. in Chemistry from the University of Pittsburgh and was a chemist in the development of thermoplastic adhesives for the National Starch and Chemical Corporation in Bridgewater, NJ.